| Literature DB >> 33358228 |
Stefania Maria Bova1, Martina Basso2, Marta Francesca Bianchi3, Laura Savaré4, Giusi Ferrara5, Eleonora Mura6, Maria Gaia Redaelli7, Ivana Olivieri8, Pierangelo Veggiotti9.
Abstract
BACKGROUND: The costs and benefits of full lockdown measures are debated. Neurologically impaired children are a vulnerable population with specific needs in terms of protection against infection and access to health services.Entities:
Keywords: COVID19 pandemic; Child neurology; Health care; Lockdown; Telemedicine
Year: 2020 PMID: 33358228 PMCID: PMC7832678 DOI: 10.1016/j.dhjo.2020.101053
Source DB: PubMed Journal: Disabil Health J ISSN: 1876-7583 Impact factor: 2.554
Description of the sample.
| Patient characteristics | Overall population |
|---|---|
| (N = 514) | |
| Male | 282 (54.9%) |
| Female | 232 (45.1%) |
| 8.8 (4.6) | |
| Italian | 449 (87.4%) |
| Other | 56 (10.9%) |
| Italian and other | 9 (1.7%) |
| Epilepsy | 317 (61.7%) |
| Cerebral palsy and other acquired encephalopathies | 67 (13.0%) |
| Inflammatory and post-infectious diseases | 17 (3.3%) |
| Degenerative and metabolic brain disorders | 41 (8.0%) |
| Neurodevelopmental disorders | 53 (10.3%) |
| Neurogenetic syndromes | 122 (23.7%) |
| Brain malformations | 43 (8.4%) |
| Others | 17 (3.3%) |
| 0 (no associated disabilities) | 149 (29.0%) |
| 1 (1 or 2 disabilities) | 138 (26.8%) |
| 2 (3 disabilities or more) | 227 (44.2%) |
| Chronic infections | 12 (2.3%) |
| Immunodeficiencies | 7 (1.4%) |
| Chronic respiratory diseases | 31 (6.0%) |
| Heart conditions | 29 (5.6%) |
| Others | 65 (12.6%) |
| Antiepileptic treatments | 265 (51.6%) |
| Immunosuppressive therapies | 15 (2.9%) |
| Other therapies | 123 (24%) |
| Regular immunisations: up to date | 449 (87.3%) |
| Pneumococcal vaccination | 330 (64.2%) |
| Seasonal influenza vaccination | 88 (17.1%) |
Legend: SD = standard deviation.
Data relevant to COVID-19 epidemiology.
| Patient characteristics | Overall population |
|---|---|
| (N = 514) | |
| Lombardy | 448 (87.2%) |
| Piedmont | 30 (5.8%) |
| Other northern Italian region | 22 (4.3%) |
| Central or southern Italian region | 14 (2.7%) |
| Family | 507 (98.6%) |
| Residential child care community | 7 (1.4%) |
| 19 (3.7%) | |
| 56 (10.9%) | |
| 127 (24.7%) | |
| 202 (39.3%) | |
| 32 (6.2%) | |
| 14 (2.7%) | |
| 28 (5.5%) | |
| 253 (49.2%) | |
| 51 (9.9%) | |
| 8 (1.6%) | |
Combined non-duplicated percentage of children who developed at least one symptom during the pre-lockdown or lockdown period.
Fig. 1Access and recourse to care services during lockdown.
Fig. 2Access to telerehabilitation for patients who had face-to-face sessions cancelled during the lockdown period.
Fig. 3Comparison between prevalence of physical symptoms in the pre-lockdown and lockdown periods by means of standardised mean differences between the two periods and OR estimated adopting a case-crossover design.
SSMD: standardised mean difference. OR: odds ratio, 95% CI.
∗ Statistically significant difference between the prevalence rates for the two periods.
Multivariate association between the considered covariates and the risk of occurrence of at least one symptom.
| Pre-lockdown | Lockdown | |||
|---|---|---|---|---|
| N° exposed (N = 207) | OR (95% CI) | N° exposed (N = 59) | OR (95% CI) | |
| Male | 108 (52.2%) | 1.00 (Ref.) | 36 (61%) | 1.00 (Ref.) |
| Female | 99 (47.8%) | 1.30 (0.73–2.33) | 23 (39%) | 0.46 (0.14–1.48) |
| 0-4 | 39 (18.8%) | 1.00 (Ref.) | 11 (18.6%) | 1.00 (Ref.) |
| 5-6 | 56 (27.1%) | 1.43 (0.55–3.68) | 10 (16.9%) | 1.26 (0.18–9.01) |
| 7-11 | 72 (34.8%) | 0.64 (0.27–1.54) | 27 (45.8%) | 1.41 (0.28–7.18) |
| ≥12 | 40 (19.3%) | 0.62 (0.24–1.55) | 11 (18.6%) | 0.53 (0.08–3.58) |
| Epilepsy | 118 (57%) | 0.48 (0.19–1.25) | 33 (55.9%) | 0.92 (0.16–5.40) |
| Cerebral palsy and other acquired encephalopathies | 30 (14.5%) | 1.73 (0.67–4.43) | 9 (15.3%) | 1.02 (0.12–9.02) |
| Inflammatory and post-infectious diseases | 6 (2.9%) | 1.00 (0.46–2.15) | 2 (3.4%) | 3.80 (0.85–17.05) |
| Degenerative and metabolic brain disorders | 14 (6.8%) | 0.28 (0.03–2.7) | 7 (11.9%) | – |
| Neurodevelopmental disorders | 17 (8.2%) | 0.37 (0.06–2.32) | 3 (5.1%) | 6.43 (0.72–57.55) |
| Neurogenetic syndromes | 51 (24.6%) | 0.78 (0.28–2.12) | 20 (33.9%) | – |
| Malformations | 21 (10.1%) | 1.03 (0.41–2.57) | 5 (8.5%) | 0.15 (0.01–2.76) |
| 0 (no associated disabilities) | 67 (32.4%) | 1.00 (Ref.) | 17 (28.8%) | 1.00 (Ref.) |
| 1 (1 or 2 disabilities) | 48 (23.2%) | 1.84 (0.84–4.04) | 9 (15.3%) | 3.52 (0.49–25.06) |
| 2 (3 disabilities or more) | 92 (44.4%) | 1.26 (0.60–2.62) | 33 (55.9%) | 3.65 (0.65–20.56) |
| Chronic infections | 4 (1.9%) | 0.85 (0.16–4.48) | 2 (3.4%) | 3.84 (0.26–56.25) |
| Immunodeficiencies | 3 (1.4%) | – | 1 (1.7%) | – |
| Chronic respiratory diseases | 16 (7.7%) | 0.97 (0.24–3.9) | 8 (13.6%) | 0.67 (0.06–7.51) |
| Heart conditions | 15 (7.2%) | 2.72 (0.78–9.45) | 3 (5.1%) | 0.76 (0.07–8.24) |
| Antiepileptic treatments | 100 (48.3%) | 1.67 (0.69–4.04) | 37 (62.7%) | 3.16 (0.66–15.17) |
| Immunosuppressive therapies | 6 (2.9%) | 4.89 (0.42–57.40) | 4 (6.8%) | – |
| Other therapies | 49 (23.7%) | 1.48 (0.70–3.16) | 15 (25.4%) | 0.45 (0.10–2.02) |
| Usual immunisations: up to date | 182 (87.9%) | 0.62 (0.24–1.56) | 52 (88.1%) | 1.74 (0.37–8.10) |
| Pneumococcal vaccination | 135 (65.2%) | 0.92 (0.46–1.84) | 40 (67.8%) | 0.56 (0.13–2.51) |
| Seasonal influenza vaccination | 33 (15.9%) | 1.36 (0.52–3.54) | 18 (30.5%) | 1.43 (0.18–11.46) |
| Residential child care community | 2 (1%) | 1.00 (Ref.) | 4 (6.8%) | 1.00 (Ref.) |
| At home with the family | 205 (99%) | 0.30 (0.03–3.74) | 55 (93.2%) | 24.14 (1.43–407.14) |
| ∗ | ∗ | 5 (8.5%) | 0.40 (0.02–9.72) | |
| ∗ | ∗ | 22 (37.3%) | 1.38 (0.18–10.66) | |
| ∗ | ∗ | 54 (91.5%) | 3.63 (1.52–8.67) | |
| ∗ | ∗ | 36 (61%) | 1.00 (0.43–2.36) | |
Legend: Logistic regression analysis to evaluate the association between the risk of developing at least one physical symptom and the variables of interest∗ = values not estimated as the variables refer only to the lockdown period- = OR < 0.001.